Longeveron’s (LGVN) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reissued their buy rating on shares of Longeveron (NASDAQ:LGVN) in a report published on Monday,Benzinga reports. They currently have a $10.00 price objective on the stock.

Separately, Maxim Group lowered their price objective on Longeveron from $15.00 to $6.00 and set a “buy” rating on the stock in a report on Tuesday, August 27th.

Longeveron Stock Performance

Shares of LGVN opened at $2.20 on Monday. The firm has a market cap of $31.59 million, a PE ratio of -0.25 and a beta of 0.36. The firm’s 50 day moving average price is $2.03 and its 200 day moving average price is $2.10. Longeveron has a twelve month low of $0.77 and a twelve month high of $23.90.

Longeveron (NASDAQ:LGVN) last released its quarterly earnings results on Wednesday, August 14th. The company reported ($1.83) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.03) by ($0.80). The business had revenue of $0.47 million for the quarter, compared to the consensus estimate of $0.53 million. Longeveron had a negative net margin of 1,513.83% and a negative return on equity of 237.57%. On average, sell-side analysts anticipate that Longeveron will post -3.89 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Longeveron stock. Renaissance Technologies LLC acquired a new position in Longeveron Inc. (NASDAQ:LGVN) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 146,700 shares of the company’s stock, valued at approximately $236,000. Renaissance Technologies LLC owned 2.31% of Longeveron as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 10.01% of the company’s stock.

About Longeveron

Longeveron Inc, a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company’s lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors.